Leriglitazone

Leriglitazone PioOH is a potent PPARγ agonist (EC50: 680 nM) that binds the receptor's ligand-binding domain, stabilizing the AF-2 surface to promote co-activator recruitment and transcriptional activity. This small molecule is a valuable research tool for studying PPARγ signaling in metabolic and neurological disease models, both in vitro and in vivo.